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Ovarian carcinomas (OC) often demonstrate rapid tumor shrinkage upon neoadjuvant chemotherapy
(NACT). However, complete pathologic responses are very rare and the mechanisms underlying the
emergence of residual tumor disease remain elusive. We hypothesized that the change of somatic BRCA1
status may contribute to this process. The loss-of-heterozygosity (LOH) at the BRCA1 locus was deter-
mined for 23 paired tumor samples obtained from BRCA1 germ-line mutation carriers before and after
NACT. We observed a somatic loss of the wild-type BRCA1 allele in 74% (17/23) of OCs before NACT.
However, a retention of the wild-type BRCA1 copy resulting in a reversion of LOH status was detected in
65% (11/17) of those patients after NACT. Furthermore, we tested 3 of these reversion samples for LOH at
intragenic BRCA1 single nucleotide polymorphisms (SNPs) and conﬁrmed a complete restoration of the
SNP heterozygosity in all instances. The neoadjuvant chemotherapy for BRCA1-associated OC is
accompanied by a rapid expansion of pre-existing BRCA1-proﬁcient tumor clones suggesting that
continuation of the same therapy after NACT and surgery may not be justiﬁed even in patients initially
experiencing a rapid tumor regression.
© 2017 Elsevier B.V. All rights reserved.Introduction
BRCA1 and BRCA2 germ-line mutations account for approxi-
mately 15% of ovarian cancer (OC) morbidity [1,2]. Tumor devel-
opment in BRCA1/2 heterozygotes usually involves a somatic
inactivation of the remaining BRCA allele, thus resulting in a
compromised DNA repair via homologous recombination., interval debulking surgery;
gosity; NACT, neoadjuvant
ebulking surgery; SNP, single
logy, N.N. Petrov Institute of
5968947.
yanitov).Accordingly, BRCA1/2-associated tumors demonstrate a high
sensitivity to several DNA-damaging drugs and PARP inhibitors,
and often have improved treatment outcomes as compared to
sporadic neoplasms [3,4].
We recently performed a pilot study of the tumor material from
BRCA1-heterozygous OC patients and obtained evidence for a rapid
selection of BRCA1-proﬁcient tumor clones during the neoadjuvant
chemotherapy (NACT). While chemonaive carcinomas subjected to
the primary debulking surgery (PDS) had expectedly a high rate (9
out of 11, 82%) of the loss-of-heterozygosity (LOH) at the BRCA1
locus, tumors removed after NACT carried a deletion of the wild-
type BRCA1 allele only in 7/24 (29%) cases. Furthermore, a direct
comparison of tumor pairs obtained before and after NACT
conﬁrmed the reversion of somatic BRCA1 status in 2 out of 3
informative patients [2]. It is highly surprising that replacement of
A.P. Sokolenko et al. / Cancer Letters 397 (2017) 127e132128the tumor mass with BRCA1-proﬁcient cells occurs already at the
very beginning of the systemic therapy course and takes such a
short period of time. Furthermore, this observation may have some
practical implications. When preoperative therapy leads to a sig-
niﬁcant reduction of the OC volume, it is a common practice to
administer the same regimen after the surgery [5,6]. However, if a
BRCA1-associated tumor restores BRCA1 function already during
neoadjuvant treatment, it is doubtful whether continuation of the
platinum therapy after the interval debulking surgery (IDS) is bio-
logically justiﬁed.
In order to validate our initial ﬁndings, we signiﬁcantly
extended the number of BRCA1-related neoadjuvant OC cases, and
undertook a systematic study of the BRCA1 status in pre- and post-
treatment tumor pairs.Materials and methods
BRCA1 germ-line mutation carriers were identiﬁed via the analysis of Slavic
founder alleles in BRCA1 gene [2,7]. Flow-chart describing the collection of heredi-
tary OC cases is presented in the Supplementary Material (Fig. S1).
Primary chemonaive cancer cells were isolated from archival cytological slides
(n ¼ 21) or tumor biopsies (n ¼ 2); post-NACT tumor samples were obtained from
surgically removed material. The dissection of tumor cells and DNA extraction are
described in Mitiushkina et al. [8]. BRCA1 LOH was assessed by real-time allele-
speciﬁc PCR (AS-PCR) using mutation- and wild-type-speciﬁc primers [9,10]. Cases
demonstrating the reversion of LOH status during neoadjuvant therapy were
additionally analyzed by at least one independent method (Supplementary
Table S2). QX100™ Droplet Digital PCR System (Bio-Rad, USA) was utilized for the
validation of LOH results obtained for BRCA1 5382insC (c.5266dupC) mutation car-
riers (see primers and probes in the Supplementary Table S1); the threshold for LOH
was a two-fold difference in the count of wild-type and mutant-speciﬁc signals.
Those samples, which failed droplet PCR ampliﬁcation, were subjected to conven-
tional allele-speciﬁc PCR with ﬂuorescently-labeled primers (Supplementary
Table S2); the intensity of peaks corresponding to the total amount of mutation-
speciﬁc and wild-type-speciﬁc PCR products was measured by Nanophore-5Table 1
LOH status in BRCA1-associated ovarian carcinomas before and after neoadjuvant therap
ID BRCA1 germ-line
mutation
TNM Histology Before NACT
LOH
status
TP53
mutati
OCT51 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma LOH WT
OCT1 4153delA [c.4034delA] T3cNxM1 Serous adenocarcinoma LOH p.V272
OCT14 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma LOH p.E298
OCT60 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma LOH p.R110
OCT24 5382insC [c.5266dupC] T3cNxM1 Serous adenocarcinoma LOH p.R248
OCT58 5382insC [c.5266dupC] T3cNxM1 Serous adenocarcinoma LOH WT
OCT21 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma LOH p.M246
OCT53 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma LOH WT
OCT5 4153delA [c.4034delA] T3cNxM1 Serous adenocarcinoma LOH c.148in
OCT52 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma LOH p. H17
OCT54 C61G [c.181T > G] T3cNxM0 Serous adenocarcinoma LOH WT
OCT50 5382insC [c.5266dupC] T3cNxM1 Serous adenocarcinoma LOH p.R248
OCT56 4153delA [c.4034delA] T3cNxM0 Serous adenocarcinoma LOH WT
OCT49 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma LOH p.R248
OCT57 C61G [c.181T > G] T3cNxM0 Serous adenocarcinoma LOH WT
OCT63 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma LOH p.G245
OCT16 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma LOH ND
OCT9 4153delA [c.4034delA] T3cNxM0 Serous adenocarcinoma No LOH WT
OCT29 5382insC [c.5266dupC] T3cNxM1 Serous adenocarcinoma No LOH c.757in
OCT62 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma No LOH WT
OCT61 4153delA [c.4034delA] T3cNxM0 Serous adenocarcinoma No LOH WT
OCT55 4153delA [c.4034delA] T3cNxM0 Serous adenocarcinoma No LOH WT
OCT59 5382insC [c.5266dupC] T3cNxM0 Serous adenocarcinoma No LOH WT
ND e no data, NI e non-informative (no LOH in cytological sample).
a CP e cyclophosphamide 1000 mg/m2 þ cisplatin 50 mg/m2; CAP e cyclophosphamid
mg/m2þ carboplatin (6 AUC); P e cisplatin monotherapy 100 mg/m2; CCbP e cyclophosp
75 mg/m2, PMMC e cisplatin 100 mg/m2 þmitomycin C 10 mg/m2, EC e epirubicin 60 m
days.
b According to Sassen S et al. [33].
c Only metastatic lesions was available for analysis.genetic analyzer (Syntol, Russia), and the ratio (R) between these values was
calculated for pre-NACT (R1) and post-NACT (R2) tumors. LOH reversion status was
assigned to the pairs with R1/R2 score equal or greater than 2. LOH reversion in the
OC pairs obtained from BRCA14153delA (c.4034delA) or C61G (c.181T > G) mutation
carriers was validated by Sanger sequencing (Supplementary Table S2).
Search for single-nucleotide polymorphisms (SNPs) within BRCA1 gene was
performed using high resolution melting analysis (HRM) and Sanger sequencing
[11]. The analysis of TP53 mutations (exons 4e8) was carried out as described in
Sokolenko et al. [12].
Immunohistochemical (IHC) staining was carried out using mouse monoclonal
antibody for BRCA1 (clone MS110; dilution 1:100; Calbiochem, Merck Millipore,
Germany), rabbit monoclonal antibody for Ki-67 (clone SP6; dilution 1:200; Spring
Bioscience, Roche, Germany) and EnVision Flex HRP visualization system (DАКО,
Carpinteria, CA). BRCA1/CEN17q probes (Abnova, Taiwan) and HER2 FISH
pharmDx™ kit were used for FISH analysis.
Results
We obtained paired tumor samples from 23 OC patients before
and after NACT. First, we determined that 17/23 (74%) pre-
treatment samples contained LOH at the BRCA1 locus. All in-
stances of LOH involved a loss of the wild-type allele. Next, we
analyzed the material surgically removed after NACT and revealed
the retention of the wild-type BRCA1 copy in 11 (65%) of 17 tumors
that have shown LOH before NACT (Table 1; Fig. 1). Among 11 tu-
mors with the restored BRCA1 heterozygosity, 8 (73%) were
exposed to 3 or more cycles of NACT, while 3 (27%) underwent
surgery after 2 cycles of systemic treatment. Patients with pre-
served LOH during NACT tended to have shorter duration of pre-
operative chemotherapy: 2 out of these 6 women received only 1
cycle of NACT (OCT57, OCT63) and 1 additional patient underwent
surgery after 2 cycles of treatment (OCT49). An apparent gain of
BRCA1 LOH after NACT was documented in 1 patient (OCT62,
Table 1).y.
Treatment
(number of cycles)a
After NACT Histopathologic
responseb
Restoration
of BRCA1
heterozygosity
on
LOH
status
TP53
mutation
CP (1), TP (1),
CP (1), CCbP (1)
No LOH p.E171D Good Yes
G TCbP (3) No LOH WT Good Yes
X CP (3) No LOH p.E298X Good Yes
P TP (6) No LOH p.R110P Good Yes
Q CP (9) No LOH WT Moderate Yes
PMMC (3) No LOH WT Moderate Yes
V CP (3) No LOH WT Moderate Yes
EC (1), TCbP (1) No LOH WT No Yes
sA CР (2), P (6) No LOH WT No Yes
9L CP (1), CCbP (1) No LOH p. H179L No Yes
CP (1), CCbP (1) No LOH WT No Yes
Q TCbP (4) LOH p.R248Q Moderate No
CP (3) LOH WT No No
Q TP (1), CP (1) LOH p.R248Q No No
CCbP (1) LOH c.898delC No No
S TP (1) LOH p.G245S No No
САР (1), topotecan (2) LOHc WT Not applicablec No
CP (2) No LOH WT Good NI
sA CP (2) No LOH WT Good NI
CCbP (2) LOH p.R196X Good NI
CP (3), CCbP (1) No LOH WT Good NI
CP (3) No LOH WT No NI
TP (1), TCbP (4) No LOH WT No NI
e 500 mg/m2 þ doxorubicin 60 mg/m2 þ cisplatin 50 mg/m2; TCbP e paclitaxel 175
hamide 600 mg/m2þ carboplatin 300 mg/m2, TP e paclitaxel 175 mg/m2þ cisplatin
g/m2 þ cyclophosphamide 200 mg/m2, topotecan e topotecan 1.5 mg/m2/day for 5
Fig. 1. BRCA1 LOH status determination in pre-NACT and post-NACT tumor tissues. Chemonaive sample from patient OCT60 (Table 1) demonstrates somatic loss of the wild-type
BRCA1 allele (top); in contrast, cancer cells excised after platinum-based therapy show the retention of the normal BRCA1 gene copy (bottom). Equivalent results are obtained by
allele-speciﬁc real-time PCR, digital droplet PCR and direct quantitation of the total amount of allele-speciﬁc PCR products.
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function in post-treatment tumor samples was related to a back
mutation of the mutant BRCA1 allele or to the expansion of pre-
existing BRCA1-proﬁcient tumor clones. To resolve this issue, we
screened normal DNA samples for linked single nucleotide poly-
morphisms (SNPs) within the BRCA1 gene. A high-molecular
weight blood DNA was available for 5 out of 11 samples with the
reversion of the LOH status. Using Sanger sequencing, we detected
SNPs in three of these patients (OCT1 [rs1799949; rs1799966];
OCT5 [rs799923]; OCT21 [rs1799949; rs1799966]). Similar to
deleterious BRCA1 mutations, these SNPs revealed LOH in the
chemonaive samples, but retained heterozygosity in the surgically
removed tumors (Fig. 2 and data not shown). Therefore, the
restoration of BRCA1 heterozygosity in OC tissue after NACT occurs
not due to a back mutation, but can be explained by a rapid se-
lection of pre-existing BRCA1-proﬁcient clones under the selective
pressure of platinum compounds.
We also analyzed paired tissue samples from the OCT14 patient
(Table 1) using IHC and FISH (Fig. 3). Neoadjuvant therapy was
accompanied by a dramatic decline of the Ki-67 index. This pa-
tient's chemonaive tumor tissuewas largely negative for BRCA1 IHC
expression, although few BRCA1-positive single cells were visible.
This is consistent with the data on a decreased stability of the
protein encoded by the BRCA1 5382insC allele [13]. A selection of
BRCA1-heterozygous cells after NACT was accompanied by an
evident increase in the BRCA1 IHC reactivity. Furthermore, a BRCA1
FISH analysis of the pre-NACT tumor tissue revealed a loss of one
copy each for BRCA1 (red signal) and the chromosome 17 centro-
meric (green signal) probes, suggesting that BRCA1 LOH isassociated with a deletion of a large region of the chromosome 17.
In agreement with the reversion of the BRCA1 LOH status, the post-
NACT tumor was biallelic for both these probes (Fig. 3). This result
was further supported by the FISH analysis of the HER2 gene, which
lies in the vicinity of the BRCA1 locus (17q12 and 17q21, corre-
spondingly; data not shown).
BRCA1 deﬁciency is poorly compatible with cell viability, thus
tumors arising in BRCA1 germ-line mutation carriers often acquire
TP53mutations in order to escape apoptosis [14,15]. Given that this
study involved a partially degraded DNA obtained from small
archival biological specimens, the TP53 DNA sequencing analysis
was conﬁned only to exons 4e8. Bearing this in mind, we identiﬁed
pathogenic TP53 mutations in 11/22 (50%) pre-NACT samples,
including 10/16 (63%) informative tumors with BRCA1 LOH and 1/6
(17%) without BRCA1 LOH (p ¼ 0.07). In post-NACT tumors, 9 out of
23 (39%) cases were positive for TP53 mutations, including 5/7
cases (71%) with BRCA1 LOH and 4/16 (25%) cases without LOH
(p ¼ 0.05) suggesting a trend to association between a mutant TP53
status and a loss of the wild-type BRCA1 allele (Table 1).
For those 11 cases where BRCA1 LOH status was restored after
NACT, the TP53 mutation status did not change in 6 cases (55%),
while in 4 cases (36%) amutant TP53 detected before NACTchanged
to wild-type thereafter, and in 1 case (9%) initially wild-type TP53
became mutant after NACT (Table 1, Fig. 4). For the 5 informative
cases where an initially detected BRCA1 LOH did not change after
NACT, the TP53 mutation status did not change in 4 (80%) cases (3
mutants and 1 wild-type), while in 1 case initially wild-type TP53
became mutated. There were no cases where a mutant TP53would
become a wild-type if BRCA1 LOH status did not change. For the 6
Fig. 2. LOH analysis of BRCA1 gene SNPs. Chemonaive tumor from patient OCT5 shows somatic LOH both the wild-type BRCA1 allele and for the linked SNPs. All three BRCA1
markers (4153delA; rs1799949; rs1799966) demonstrate restoration of heterozygosity in the post-NACT samples. Similar results were obtained for two remaining tumors with
informative SNPs (OCT1 and OCT21; data not shown). Taken together, these observations provide strong evidence that restoration of intratumoral BRCA1 function occurs via
selection of preexisting BRCA1-proﬁcient tumor clones, but not due to back mutation.
Fig. 3. IHC and FISH analysis of pre- and post-NACT ovarian cancer samples. Neoadjuvant chemotherapy results in expansion of BRCA1-proﬁcient cells, as evidenced both by IHC
analysis of BRCA1 expression and the selection of BRCA1 biallelic cells determined by FISH. See also comments in the text.
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mutation status (WT) did not change after the treatment in 4 cases
(67%). In all these 4 cases the BRCA1 LOH status did not change
either. Nevertheless, in 2 other cases the TP53 mutation status was
different before and after treatment. In one case (OCT29), a mutant
TP53 in the pre-NACT tumor became WT in the post-NACT tumor.
Both samples from this case revealed no LOH for BRCA1. In the
second case (OCT62), an initially WT TP53 acquired a pathogenicmutation after the treatment. Interestingly, this was the only
instance, inwhichwe failed to detect BRCA1 LOH in the chemonaive
tumor, while observing a deletion of the wild-type BRCA1 in the
post-NACT neoplastic tissue.
A histopathologic tumor response was observed in 7 out of 11
(64%) tumors with the reversion of BRCA1 LOH status, including 4
good and 3 moderate responders. In contrast, only 1 (20%) out of 5
informative cases with preserved LOH before and after NACT
Fig. 4. BRCA1 LOH and TP53 status in pre- and post-NACT ovarian carcinomas. TP53mutations tend to occur more often in tumors with the somatic deletion of the wild-type BRCA1
allele. Change of BRCA1 LOH status during NACT is accompanied by the change of TP53 mutation status in some but not all tumor pairs.
A.P. Sokolenko et al. / Cancer Letters 397 (2017) 127e132 131showed a moderate histopathologic response (p ¼ 0.14). Among 6
tumors with the retention of BRCA1 heterozygosity in the chemo-
naive tumor tissue, 4 patients (67%) demonstrated a good histo-
pathologic response (Table 1).
Discussion
The utility of the neoadjuvant therapy for the treatment of
ovarian cancer is a subject of intense debates [16e21]. The preop-
erative use of platinum agents usually results in signiﬁcant reduc-
tion of tumor volume, thus allowing for a less traumatic surgery
and a low perioperative morbidity. However, opponents of NACT
insist that anticancer drugs cannot efﬁciently penetrate large tumor
masses, thus causing many OC cells to escape drug uptake before
the surgery. Furthermore, NACT may convert OC lumps into
macroscopically invisible lesions, which can be missed during a
surgical inspection. In addition, the presence of a high tumor
burden at the beginning of the therapy increases the chances of
efﬁcient selection of resistant tumor clones during the preoperative
exposure to platinum agents. A direct comparison of OC treatment
schemes involving NACT followed by interval debulking surgery
and postoperative systemic therapy versus PDS followed by adju-
vant therapy is critically compromised by a huge variability of
surgical attitudes between different hospitals. It is acknowledged
that even if a tumor rapidly shrinks upon the neoadjuvant treat-
ment and all visible malignant lumps are successfully removed
during IDS, the presence of residual cancer cells in surgically
removed tissues is associated with a high risk of relapse despite the
continuation of an apparently effective systemic therapy [21]. The
current study provides a mechanistic explanation to this phe-
nomenon, at least for cancers arising in BRCA1mutation carriers: in
contrast to primary LOH-bearing OC samples, the systemically
treated tumor tissues often retain a normal copy of BRCA1 gene by
the time of surgery and, therefore, are likely to be non-responsive
to the continuing platinum-based therapy.
The emergence of tumor resistance during a systemic therapy is
well known, however, this process was believed to take at least
several months [22]. Here we demonstrate that depletion of
BRCA1-deﬁcient tumor cells in OCs may occur within a few weeks
of the neoadjuvant treatment, and during this time tumors become
rapidly repopulated by the BRCA1-proﬁcient tumor clones. Given
that BRCA1-proﬁcient cells are hardly detectable in LOH-carrying
tumors at the start of the therapy, it seems likely that the death
of platinum-sensitive cells is accompanied by a very rapid prolif-
eration of platinum-resistant clones to form a visible tumor mass
within such a short period of time. Interestingly, recent studiesdemonstrate an active interaction between drug-sensitive and
-resistant clones during therapy: dying cancer cells can secrete
molecules triggering proliferation and expansion of the subtle
fraction of treatment-refractory cells [23].
Restoration of BRCA1/2 function upon emerging resistance to
platinum drugs or PARP inhibitors has been already demonstrated
by several investigators [24e32]. Our study has essential differ-
ences as compared to the previous reports. First, the above studies
involved mainly heavily pretreated patients, while we analyzed
tumors exposed to a limited number of therapeutic cycles. Second,
restoration of the BRCA1 function during palliative treatment of
metastatic OCs often involves additional genetic events directly in
the germ-line mutation-bearing allele restoring the open reading
frame of BRCA1. Some secondary mutations are located in the vi-
cinity of the primary one, thus, resulting in a functional BRCA1
protein, yet carrying small differences from the WT at the nucleo-
tide sequence level. Other platinum-resistant tumors are charac-
terized by a complete restoration of the wild-type BRCA1 sequence
caused by a back mutation. Here we provide a convincing evidence
that the presence of thewild-type BRCA1 in tumormasses removed
after a neoadjuvant therapy can be explained by selection of pre-
existing BRCA1-proﬁcient cells rather than by a back mutation
(Fig. 2). This conclusion is in agreement with the study of Martins
et al. [15] showing that a somatic deletion of the BRCA1 wild-type
allele is not necessarily the very ﬁrst event in the BRCA1-driven
tumorigenesis, and that tumors arising in BRCA1 mutation-
carriers often contain a fraction of malignant cells with a retained
BRCA1 function. Furthermore, data on the heterogeneity of BRCA1
LOH and TP53mutations conﬁrm observations of Martins et al. [15]
that no obligatory temporal order for these molecular events exists
during tumor development (Table 1, Fig. 4).
Several limitations of the study have to be acknowledged,
though. First, the determination of the LOH status did not account
for the possible intratumoral heterogeneity. For example, an
apparent gain of LOH during NACT in the case OCT62 could be
explained not by the true absence of LOH in the chemonaive tumor,
but by the existence of genetically distinct tumor clones in the
beginning of the therapy. Second, manipulations with tiny tumor
masses, such as cytological slides or post-NACT samples, are tech-
nically challenging. Nevertheless, a signiﬁcant impact of technical
difﬁculties on our results seems unlikely. For example, several OC
samples with BRCA1 heterozygosity restored upon NACT still car-
ried TP53mutations, whichwouldn't be possible if tumor cells were
dissected incorrectly. Third, although all therapeutic schemes were
platinum-based, there were signiﬁcant interpatient variations
concerning the composition of cytotoxic cocktails and the number
A.P. Sokolenko et al. / Cancer Letters 397 (2017) 127e132132of therapy cycles. For example, two patients included in this study
received only one cycle of chemotherapy and demonstrated a
preserved LOH status after NACT. It is questionable whether the
data obtained for these women should be considered.
It remains to be further investigated, to what extent the
reversion of the LOH status in BRCA1-mutated tumors after
chemotherapy may inﬂuence their sensitivity to a subsequent
treatment. In theory, a somatic inactivation of the wild-type BRCA1
allele should correlate with the sensitivity to a platinum-based
therapy, while restoration of the BRCA1 heterozygosity after
NACT may call for alternative treatment options. In this respect,
our study may be practice-changing and lead to a re-evaluation of
post-NACT treatment options for hereditary BRCA1 mutation-
positive OC patients. Our results call for a separate clinical trial,
in which the BRCA1 LOH status would be evaluated before and
after NACT, on the one hand, and the efﬁciency of the same
chemotherapeutic agents as before the surgery would be
compared with alternative agents, to which the patients has not
been exposed previously, on the other hand.
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